{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:13:55Z","timestamp":1773926035303,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jaccao.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:05:32Z","timestamp":1739905532000},"page":"185-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Empagliflozin to Prevent Doxorubicin\u00a0Cardiotoxicity"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-4852","authenticated-orcid":false,"given":"Zhen","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2025.01.005_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaccao.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A\u00a0population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jaccao.2025.01.005_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaccao.2024.12.004","article-title":"SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics","volume":"7","author":"Medina-Hern\u00e1ndez","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.01.005_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jaccao.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","article-title":"Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways","volume":"21","author":"Baris","year":"2021","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jaccao.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jaccao.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jaccao.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.14744\/AnatolJCardiol.2023.2825","article-title":"Dapagliflozin may protect against doxorubicin-induced cardiotoxicity","volume":"27","author":"Ulusan","year":"2023","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jaccao.2025.01.005_bib9","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaccao.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2025.01.005_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left ventricular mass change after anthracycline chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacbts.2022.09.010","article-title":"Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury","volume":"8","author":"Guo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaccao.2025.01.005_bib14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cmet.2023.02.006","article-title":"Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity","volume":"35","author":"Ozcan","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jaccao.2025.01.005_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaccao.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaccao.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1042\/BCJ20160385","article-title":"Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy","volume":"473","author":"Bartlett","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.jaccao.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","article-title":"Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:05:37Z","timestamp":1739905537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666087325000122"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin to Prevent Doxorubicin\u00a0Cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.12.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}